IND-Enabling Program Support
Sinclair Research offers full-service IND-enabling toxicology and safety pharmacology services at a single research site. Whether your program is in late-stage discovery or entering clinical trials, Sinclair Research provides the services you need, the data you expect and the customer service you deserve.
The services you expect. The data you need. The customer experience you deserve.
Built on more than 50 years of experience, Sinclair Research provides research services to support biopharmaceutical, animal health and medical device development programs. As one of the largest nonclinical CROs in North America, Sinclair Research’s scientific and technical expertise can provide you with the services you need, the data you expect, and the customer experience you deserve! Contact our team to discuss your upcoming research and meet with our scientific experts to discuss how to reach your next development milestone.
Our Latest News
Sinclair Research, a leading provider of nonclinical research services, has named Dr. Sandra Love, PhD as Director of Safety Pharmacology. In this role, Dr. Love will lead Sinclair’s Safety Pharmacology program and consult on the design and development of in vivo pharmacology disease models to support current and prospective customers.
Sinclair Research, a leading provider of nonclinical contract research services, today announced a strategic partnership with Bolder BioPATH, a premier provider of pharmacology and pathology services specializing in in vivo models of Rheumatoid Arthritis, Osteoarthritis, Inflammatory Bowel Disease, and other autoimmune and inflammation models.
Sinclair Research, a leading provider of nonclinical contract research services, today announced the successful GLP validation of its Safety Pharmacology services in partnership with CorDynamics, a premier provider of cardiovascular toxicology and safety pharmacology contract research services.
Our virtual audit solution provides a fully customizable alternative to in-person facility qualifications, audits and tours!
Sinclair Research’s virtual audits offer an innovative way to overcome the obstacles raised by the global pandemic. Virtual audits are built with flexibility in mind, allowing you to customize your audit to meet your individual needs. Our secure virtual platform is designed to quickly and effectively share the information you need to conduct a comprehensive virtual audit or facility tour. From the initial planning meeting to the completion of your virtual audit, Sinclair Research’s team of scientific and quality experts will be at your service, just as they would if you were physically on site.
Our Recent Events
Watch our latest on-demand webinar: "505(b)(2) Formulation Considerations for New Topical Drug Products"
Watch our latest on-demand webinar as Tioga Research CEO, Dr. John M. Newsam, and Sinclair Research’s Director of Toxicology and Dermatology, Dr. Jeffrey Klein, PhD, DABT share their insight on how 505(b)(2) topical drug products extend market exclusivity!
Watch our on-demand webinar “How Do I Get Into Phase 1 Trials with My Compound?” Presented by Sinclair Research’s Senior Vice President of Research, Dr. Scott E. Boley, PhD, DABT, this live webinar will explore how to get your compound into Phase 1 trials.